Biologic teclistamab shows promise in treatment of refractory multiple myeloma in phase 1 drug study
1. Patients on the recommended phase 2 dosage of teclistamab had no dose-limiting adverse events. 2. There was a 65% ...
Tag: relapsed refractory multiple myeloma
Isatuximab improves progression-free survival in patients receiving carfilzomib–dexamethasone treatment for multiple myeloma
1. Higher rates of treatment response were observed in patients receiving isatuximab with carfilzomib–dexamethasone than carfilzomib–dexamethasone alone. 2. Improved median ...
